Accendra Health Inc (ACH)vsVertex Pharmaceuticals Inc (VRTX)
ACH
Accendra Health Inc
$3.58
-4.28%
HEALTHCARE · Cap: $285.88M
VRTX
Vertex Pharmaceuticals Inc
$429.82
+1.13%
HEALTHCARE · Cap: $107.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 342% more annual revenue ($12.22B vs $2.76B). VRTX leads profitability with a 35.5% profit margin vs -39.9%. ACH appears more attractively valued with a PEG of 0.70. VRTX earns a higher WallStSmart Score of 66/100 (B-).
ACH
Hold48
out of 100
Grade: D+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACH.
Margin of Safety
+57.2%
Fair Value
$992.87
Current Price
$429.82
$563.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 24 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 2.9%
ROE of -163.8% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ACH
The strongest argument for ACH centers on PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ACH
The primary concerns for ACH are EPS Growth, Market Cap, Operating Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ACH profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
ACH carries more volatility with a beta of 1.70 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 48/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Accendra Health Inc
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Aluminum Corporation of China Limited, manufactures and sells alumina, primary aluminum and energy products in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?